Second primary lung malignancy in head and neck cancer patients  by Dequanter, D. et al.
European Annals of Otorhinolaryngology, Head and Neck diseases (2011) 128, 11—13
ORIGINAL CLINICAL RESEARCH
Second primary lung malignancy in head and neck
cancer patients
D. Dequantera,∗, M. Shahlaa, I. Lardinoisa, O. Gilbertb, O. Hanquetb,
G. Tragasb, A. Van Meerhægheb, P. Lothairea
a Service de chirurgie, CHU Charleroi, rue de Gozée 706, 6110 Montigny-le-Tilleul, Belgium
b Service de pneumologie, CHU Charleroi, rue de Gozée 706, 6110 Montigny-le-Tilleul, Belgium







Introduction: Second primary lung cancer (SPLC) is generally of poor prognosis in patients
presenting with head and neck cancer.
Methods: Between January 2000 and June 2008, 39 patients with head and neck squamous-cell
carcinoma (HNSCC) patients diagnosed with SPLC were included.
Results: Fourteen SPLC were classiﬁed as synchronous and 25 as metachronous. SPLC and HNSCC
staging correlated (P = 0.0496). Patients withmetachronous tumor showed longer median overall
survival than those with synchronous tumor (92.9months versus 15.7months; Hazard ratio (HR),
0.323; 95% CI, 0.042—0.559; P = 0.0045). In the subgroup of 11 patients with SPLC diagnosed
more than 5 years after HNSCC, prognosis was better (128.1 versus 29.7months; HR, 0.288; 95%
CI, 0.053—0.353; P < 0.0001).
Discussion: In the present study, in contrast to the literature, improved prognosis and survival
were found in the subgroup in which SPLC developed more than 12months after initial HNSCC
diagnosis, and even more speciﬁcally in that in which SPLC developed more than 5 years after
initial HNSCC diagnosis.
Conclusion: SPLC in HNSCC is generally described as unequivocally aggressive and of poor prog-
nosis. Metachronous SPLC, however, especially when diagnosed more than 5 years after HNSCC,
was clearly associated with better prognosis.
© 2010 Published by Elsevier Ma
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ntroductionynchronous or metachronous diagnosis of a second primary
ung cancer (SPLC) in patients with head and neck squamous-
ell carcinoma (HNSCC) is a management challenge: ongoing
NSCC treatment has to be combined with treatment of
second tumor, with its own prognostic speciﬁcity. Asso-
.





















































Figure 1 Overall survival in the 39 patients according
to chronological sequence of tumor diagnosis (blue line:
metachronous tumor; purple line: synchronous tumor).




















iated treatment is to be assessed in terms not only of
umor response but also of cumulative toxicity. Prognosis
s reserved; however, satisfactory 5-year survivorship can
e achieved by early diagnosis and appropriate combined
herapy.
ethods
f the 412HNSCC patients treated in our department
etween January 2000 and June 2008, 39 retrospec-
ively selected patients presenting with synchronously or
etachronously diagnosed SPLC were followed up to deter-
ine prognosis. SPLC onset was classiﬁed as synchronous
f diagnosis was made within the 12 months following that
or HNSCC, and as metachronous in case of longer interval.
mpact of onset and of tumor site were assessed.
Follow-up comprised 3-monthly consultation and clinical
nd paraclinical check-up for the ﬁrst 2 years following ini-
ial treatment, with twice-yearly follow-up (FU) in the 3rd
nd 4th years, and a single consultation in year 5. Thoracic
T scan was notably scheduled twice-yearly, whatever the
nitial HNSCC grade.
All clinical and histological data underwent uni- and mul-
ivariate analysis to deﬁne groups at risk of recurrence
r of death. Distributions were estimated on the Kaplan-
eier method and compared by Logrank test for categoric
ariables; continuous variables were adjusted on a semi-
arametric univariate Cox model.
esults
hirty-two patients were male; median age was 58 years
range, 43—43 years). The primary HNSCCwas situated in the
arynx (16 cases), hypopharynx (seven), oropharynx (seven)
r oral cavity (nine); tumor grade was grade I (in three
ases), II (seven), III (13) or IV (16). Median time to SPLC
iagnosis was 24.5months (range, 0—204mo). Fourteen
PLCwere classiﬁed as synchronous and 25 as metachronous.
Most synchronous SPLC (11/14) were diagnosed dur-
ng extension assessment. In three cases, complementary
adiologic examination was performed in the light of the
ymptomatology. Metachronous SPLC were diagnosed for-
uitously in six cases, after assessment for respiratory
nfection in ﬁve, and during extension assessment in 12.
Nineteen patients developed squamous-cell carcinoma,
our adenocarcinoma, three bronchoalveolar carcinoma, six
mall cell carcinoma and one carcinoid tumor, staged as in
itu (one patient), or as stage I (six), II (ﬁve), III (eight) or
V (15). Eight of the 15 stage IV patients showed remote
etastasis and seven contralateral pulmonary metastasis.
Treatment was determined by tumor grade. Early-grade
PLC associated with early-grade HNSCC was managed by
ocal surgery for the SPLC and local surgery or radiotherapy
or the HNSCC, treatment and sequence depending on
he patient’s general health status. Advanced-grade tumor
as managed by chemotherapy, with subsequent sequences
etermined by tumor response. In metachronous SPLC,
reatment was adapted to tumor grade: surgery in early-
rade SPLC, concomitant chemo- and radiotherapy in grade
II, and chemotherapy in grade IV; thus, nine patients were




Oetween head and neck squamous-cell carcinoma and second
rimary lung cancer diagnoses: more (blue line) or less than
years (purple line).
nd one atypic resection). Two patients showed postopera-
ive pneumopathy.
SPLC and HNSCC grades correlated (P = 0.0496). Six of
he 27 patients assessed and followed up in the same cen-
er showed complete remission. At a median 53.5months’
U, nine patients were free of recurrence/progression and
nother nine were alive. Median survival in all 39 patients
as 12months, versus 3.7months in the 15 grade IV patients.
verall survival was longer in case of metachronous then
ynchronous SPLC (92.9months versus 15.7months; Hazard
atio (HR), 0.323; 95% CI, 0.042—0.559; P = 0.0045) (Fig. 1).
n the subgroup of 11 patients with SPLC diagnosed more
han 5 years after HNSCC, prognosis was better (128.1 ver-
us 29.7months; HR, 0.288; 95% CI, 0.053—0.353; P < 0.0001)
Fig. 2).
iscussion
ynchronous or metachronous diagnosis of SPLC in HNSCC
atients is a serious management challenge.
Schwartz et al. [1] reported a high probability of SPLC in
atients initially treated for aggressive HNSCC (41% and 59%
espectively, for synchronous and metachronous tumors).
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probability of developing SPLC diminished to 22%. SPLC is
considered to be of very bad prognosis, coming on top of
the poor prognosis associated with HNSCC, which is often
diagnosed at an advanced stage [2].
Improved 5-year survival can, however, be hoped for
given adapted combined therapy [3]. Thus, Di Martino et al.
[4] reported that aggressive treatment gave the best results,
with 5-year survival of 66.8%.
More speciﬁcally, in the present study, improved survival
and prognosis was found in the subgroup of primitive HNSCC
followed by SPLC more than 12months after the ﬁrst diag-
nosis, and even more speciﬁcally in the subgroup of SPLC
diagnosed more than 5 years after the initial diagnosis of
HNSCC.
Massard et al. [5], in contrast, reported no impact of SPLC
onset interval, nor of its histologic classiﬁcation.
According to Schwartz et al., however, survival after
diagnosis of a second cancer was signiﬁcantly affected by
SPLC location [1].
Survival is also related to SPLC grade at diagnosis, par-
ticularly in case of initial associated ganglion invasion [4].
De Mones et al. [6] found 5-year survival to be related to
SPLC grade at diagnosis, ranging from 46% for grade I, 13%
for grade II and 0% for grades III and IV. Likewise, when no
ganglion invasion was associated, survival was 67% versus 0%
in case of associated ganglion invasion (N1-3).
Massard et al. [7] also found survival to be related to
SPLC grade at diagnosis: mean overall survival was 28.7%,
but 33.3% in grade I tumor, 19.2% in grade II, and 30.2% in
grade III. On the other hand, survival was unaffected by the
interval to the onset of SPLC or its location. Likewise, Di Mar-
tino et al. [4] reported identical prognoses for synchronous
and metachronous SPLC.
The median interval to SPLC after HNSCC is generally
estimated at 36 months [8—10]. In the present study, the
interval was 24.5months (range, 0—204 mo). Quadrelli et
al. [11], however, reported intervals of less than 2 years.
In the present study, however, prognosis was signiﬁ-
cantly better in metachronous (> 12month interval) than in
synchronous SPLC (P = 0.0045), and even more so for inter-
vals exceeding 5 years (128.1months versus 29.7months)
(P < 0.0001).
Schwartz et al. [1] found, on multivariate analysis, that
the occurrence of a second cancer was affected by two
factors: as well as the primitive site, already known to be
relevant, patient age emerged as a risk factor.
In the present study, squamous-cell carcinoma was, his-
tologically, the most frequent form of SPLC. Likewise Atabek
et al. [12] reported SPLC histologically compatible with
squamous-cell carcinoma in 63% of their patients; 20 of
their SPLC were synchronous and 47metachronous (diag-
nosed more than 12months after initial diagnosis of HNSCC);
only 11% of the metachronous SPLC were grade I.
In comparison, in the present study, 24 patients had syn-
chronous and a majority (n = 25) metachronous SPLC. Six
[ts 13
f the 39 had grade I tumor at diagnosis; most had grade
V, which conﬁrms the need for early screening to improve
rognosis.
onclusions
PLC in HNSCC is generally described as unequivocally
ggressive and of poor prognosis. Metachronous SPLC, espe-
ially when diagnosed more than 5 years after HNSCC,
owever, was clearly associated with better prognosis.
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